Transcatheter aortic valve implantation (TAVI) appears to be equivalent to surgical aortic valve replacement (SAVR) with regard to clinical end points in high-risk and intermediate risk patients. Major landmark trials, such as Placement of Aortic Transcatheter Valves (PARTNER) trials 1 and 2 and US CoreValve show similar hemodynamic responses and left ventricular remodeling after both procedures. Real-life nonrandomized studies, however, suggest that TAVI may result in a somewhat better hemodynamic response and, therefore, a more favorable left ventricular remodeling than after SAVR for the first few years of follow-up. Further, there are fewer cases of prosthesis patient mismatch and more cases of paravalvular leak and conduction system abnormalities that affect the left ventricular remodeling process with TAVI than with SAVR. Overall, TAVI may be considered superior to SAVR in high-risk patients whose clinical outcome depends on a favorable remodeling process.